Interfering with the p38 pathway by the use of the specific inhibitor XG-102 has been shown to reduce intraocular inflammation [187] in a dose-dependent manner [188] in a rat LPS-induced uveitis model and also in patients with post-operative inflammation after anterior and posterior segment combined surgery, glaucoma surgery or complex posterior segment surgery [189,190,191]. Here, MAPK1 is linked to glaucoma.